Autopsy report · NCT03437200

Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Poor accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 11 months before it started.
Ran for about 3 years 9 months before it stopped.
8 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Sponsor type: University, hospital or other
Conditions: Inoperable œsophageal Cancer
Interventions: Nivolumab; Ipilimumab; Chemoradiation
Participants: 8
Sites: 7
Countries: France, Spain

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.